NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

Britain agrees deal to provide free antibody tests

Published 21/05/2020, 14:02
© Reuters. Outbreak of the coronavirus disease (COVID-19) in Brighton
ROG
-

LONDON (Reuters) - Britain has agreed a deal to acquire antibody tests, a spokesman for Prime Minister Boris Johnson said on Thursday, saying the tests would be free and health and care workers would be prioritised.

Mass antibody testing is being considered by many countries as a way to speed the reopening of economies devastated by lockdowns and to introduce more tailored social distancing measures.

Britain has been in talks with Swiss drugmaker Roche Holding (SIX:ROG) AG to buy an accurate COVID-19 antibody test, following the lead of the European Union and United States which have already given preliminary approval to the tests.

"Have we now agreed a deal on the antibody testing? The answer to that is yes," the spokesman told reporters, adding that health minister Matt Hancock would offer more details later on Thursday.

The antibody tests - also known as a serology test - show who has been infected, although it is not yet clear whether the presence of antibodies to the new coronavirus, SARS-CoV-2, confers permanent immunity.

© Reuters. Outbreak of the coronavirus disease (COVID-19) in Brighton

Earlier this month, the spokesman said there was the possibility of issuing some kind of certificate based on immunity but that scientists still needed to know more about that subject area.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.